Ani Pharmaceuticals (ANIP) Gross Margin (2012 - 2026)

Ani Pharmaceuticals has disclosed Gross Margin across 15 years of filings, most recently posting 60.59% for Q1 2026.

• Gross Margin for Q1 2026 came in at 60.59%, down 236.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 60.83% (up 149.0% YoY), and the FY2025 annual result was 61.36%, up 209.0% from the prior year.
• Gross Margin came in at 60.59% for Q1 2026 at Ani Pharmaceuticals, up from 59.42% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 64.7% in Q2 2025 to a low of 46.85% in Q1 2022.
• The 5-year median for Gross Margin is 60.59% (2026), against an average of 59.83%.
• Across the five-year window, Gross Margin jumped 12529 bps in 2022 and slumped 604 bps in 2024, its largest moves.
• Ani Pharmaceuticals' Gross Margin stood at 61.45% in 2022, then declined by 3 bps to 59.42% in 2023, then retreated by 3 bps to 57.87% in 2024, then gained by 3 bps to 59.42% in 2025, then gained by 2 bps to 60.59% in 2026.
• The last three Gross Margin figures came in at 60.59% (Q1 2026), 59.42% (Q4 2025), and 59.01% (Q3 2025), per Business Quant data.